<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000390295"><TermName>transferrin-CRM107</TermName><TermPronunciation>(tranz-FAYR-in...)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of brain tumors. Transferrin-CRM107 is made by linking a diphtheria toxin to transferrin, a protein that binds to fast growing cells, such as tumor cells. The diphtheria toxin then kills the tumor cells. Transferrin-CRM107 is a type of immunotoxin.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000713175" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;transferrin-CRM107&quot;" language="en" id="_3"/><MediaLink ref="CDR0000713176" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;transferrina-CRM107&quot;" language="es" id="_4"/><SpanishTermName>transferrina-CRM107</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de tumores cerebrales. La transferrina-CRM107 se elabora al unir toxina de difteria a la transferrina, una proteína que se une a las células de crecimiento rápido, como las células tumorales. La toxina de difteria luego destruye las células tumorales. La transferrina-CRM107 es un tipo de inmunotoxina.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2004-09-25</DateFirstPublished><DateLastModified>2008-03-13</DateLastModified></GlossaryTerm>
